KZIA Company Profile and Key Details

KZIA has shown mixed momentum, gaining 9.32% over the past week and 0.57% over the past quarter, though year-to-date performance is up 2.18%. Short-term trend indicators are bullishly aligned (SMA20 46.74%, SMA50 28.13%, SMA200 17.34%). The stock’s 14-day RSI is 69.24 (firm momentum), while the ATR of 0.87 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -49.14% below its high and over 209.44% above its low. Average 10-day trading volume of 97.99 thousand shares is below the 3-month average of 222.40 thousand, indicating normal recent market interest.

Kazia Therapeutics Limited generated EPS of -$12.31 over the past year. Five-year average earnings growth is 25.92%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $13.00. The high target offers 166.31% upside. The low target suggests 73.1% downside. The mean target is $16.80. This offers 123.7% upside. Kazia Therapeutics Limited earnings surprise history is a mixed track record. The quarter that ended November 07, 2025, missed forecasts by 6529.86%. The prior quarter beat by 6529.71%. Over the last six quarters, Apple has recorded several small beats. These include 108.12% in November 19, 2024.

Kazia Therapeutics Limited has 1.36 million shares outstanding. The public float is 422.58 million shares, elevated short interest at 2.83% of float. This equals 31.07 thousand shares. The short ratio is 0.05 days. Institutional investors hold 9.73% of the float. Insiders own 8.48%.

Kazia Therapeutics Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.54. This means the shares are trading above this model’s fair value.

Kazia Therapeutics Limited (NASDAQ:KZIA) shares are flat 2.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Kazia Therapeutics Limited trading at a premium to the broader market with a P/E of -0.81. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.60, suggesting 67.78% upside. Our AI forecast model points to short-term strength (8.52% over two weeks), a medium-term fall (-39.01% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Kazia Therapeutics Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.52%, with price expected at $8.15 by April 01, 2026, within a range of $6.93 to $9.37 3-Month Outlook: Projected fall of -39.01%, reaching $4.58 by June 16, 2026, with a range of $2.46 to $6.48. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by March 18, 2027, within a range of $0.00 to $4.51.

Kazia Therapeutics Limited (NASDAQ:KZIA) closed at $7.51 USD, losing -$0.02 (-0.27%) from the previous close of $7.53. The stock is currently mid-range between its 52-week high and low $2.86 and $17.40. With a market capitalization of about $12.16 million, Kazia Therapeutics Limited is classified as a micro-cap and shows higher-than-market volatility (beta ~1.63). Key stats such as the average daily volume over the past year has been around 222.52 thousand shares, in line with its 52-week average. Headquartered in Sydney, NSW, Kazia Therapeutics Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO John Edwin Friend, the company employs approximately 9 people and listed since January 06, 1999. Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs.

Kazia Therapeutics Limited trades at a P/E ratio of -0.81, slightly below the S&P 500 average, with a price-to-sales ratio of 408.38 and a price-to-book ratio of -1.98 indicating negative book value, which may reflect financial stress. The P/FCF stands at -4.07, also below market averages.